N/A N=440 Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Proportion of Responders at the End of 8-week — 60.6; 36.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants
Phase 3 N=242 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
Prostatitis
Primary: Clinical Success — 46; 48; 52 Participants
Phase 3 N=324 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Primary: Decrease in the NIH-CPSI Total Score by at Least 6 Points — 103; 38 Participants
Phase 3 N=272 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis
Primary: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks — 68; 66 Participants — p=0.99
Phase 2 N=62 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 5.5; 5.6; -1.4; -1.0 units on a scale
Phase 2 N=151 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary: National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score. — 26.0; 26.8; 27.9; -12.1 Units on a 0 to 43 scale
Phase 3 N=139 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)
Chronic Prostatitis · Chronic Pelvic Pain Syndrome
Primary: Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) — 47; 33 participants — p=<0.05
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
N/A N=69 Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain
Chronic Pelvic Pain · Endometriosis
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form (SF) 4a Between Groups — 59.2; 63.4 t-scores — p=0.038
Phase 2 N=100 An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Primary: Change of IPSS at the 6th Week Compared With Baseline(Intention to Treat) — 7.26; 2.34 units on a scale — p=< 0.01
Phase 3 N=528 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hypertrophy
Primary: IPSS Change From Baseline — -5.6 Units on a scale — p=<0.001
N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
N/A N=279 Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Urinary Incontinence
Primary: Amount of Urinary Leakage — 23.2; 22.3; 31.5; 11 grams
Phase 2 N=96 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .594 Adverse Events — p==0.219
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
N/A N=687 PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy
Infection
Primary: Percentage of Subjects That Experienced Infection, Urinary Retention or Bleeding Requiring Intervention Within 7 Days of Biopsy Based on Transrectal Ultrasound Guided…
Phase 2 N=134 Botulinum Toxin Injection for the Management of BPH
Benign Prostatic Hyperplasia
Primary: Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. — 46; 50 participants — p=<0.05
N/A N=20 Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Mindfulness · Complementary Medicine
Primary: Global Response Assessment (GRA) — 2; 0; 1; 3 participants
Phase 3 N=369 Complementary and Alternative Medicine for Urological Symptoms(CAMUS)
Urological
Primary: Mean and Standard Deviation of the Participant American Urological Association (AUA)Symptom Score Between Baseline and Week 72 for CAMUS Participants. — -2.20; -2.99…
Phase 4 N=72 Interstitial Cystitis: Examination of the Central Autonomic Network
Interstitial Cystitis/Painful Bladder Syndrome · Myofascial Pelvic Pain
Primary: Total Score on Genitourinary Pain Index (GUPI) Scale — 24.4; 22.2; 2.35; 29.25 score on a scale
N/A N=170 Real World Data on Management of Male LUTS
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants